Chapter 1: What’s new in the treatment of chronic kidney disease?

An overview of chronic kidney disease (CKD), in those with and without diabetes. The emerging role of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the role of CKD treatment is discussed, including a new US Food and Drug Administration (FDA)-approved indication.

← Back to Conversations with Leaders: CKD